Fol. Biol. 2024, 70, 262-269
https://doi.org/10.14712/fb2024070050262
Down-regulation of lncRNA EMX2OS Is Associated with the Prognosis of Patients with Cervical Squamous Cell Carcinoma and Regulates Tumour Cell Progression via miR-574-5p
References
1. 2020) A review of cervical cancer: incidence and disparities. J. Natl. Med. Assoc. 112, 229-232.
, A., David-West, G., Clare, C. A. (
2. 2022) Radiotherapy of cervical cancer. Cancer Radiother. 26, 298-308.
< , C., Peignaux, K., Escande, A. et al. (https://doi.org/10.1016/j.canrad.2021.11.009>
3. 2022) Targeting non-coding RNAs to overcome cancer therapy resistance. Signal Transduct. Target. Ther. 7, 121.
< , B., Dragomir, M. P., Yang, C. et al. (https://doi.org/10.1038/s41392-022-00975-3>
4. 2020) Comprehensive analysis of aberrantly expressed long non‑coding RNAs, microRNAs, and mRNAs associated with the competitive endogenous RNA network in cervical cancer. Mol. Med. Rep. 22, 405-415.
< , P., Zhang, W., Chen, Y. et al. (https://doi.org/10.3892/mmr.2020.11120>
5. 2020) LncRNA EMX2OS induces proliferation, invasion and sphere formation of ovarian cancer cells via regulating the miR-654-3p/AKT3/PD-L1 axis. Cancer Manag. Res. 12, 2141-2154.
< , M., Fang, M., Wang, C. et al. (https://doi.org/10.2147/CMAR.S229013>
6. 2018) The downregulation of lncRNA EMX2OS might independently predict shorter recurrence-free survival of classical papillary thyroid cancer. PLoS One 13, e0209338.
< , Y., Feng, C., Liu, T. et al. (https://doi.org/10.1371/journal.pone.0209338>
7. 2009) Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat. Protoc. 4, 44-57.
< , D. W., Sherman, B. T., Lempicki, R. A. (https://doi.org/10.1038/nprot.2008.211>
8. 2020) Downregulation of enhancer RNA EMX2OS is associated with poor prognosis in kidney renal clear cell carcinoma. Aging (Albany NY) 12, 25865-25877.
< , H., Chen, H., Wan, P. et al. (https://doi.org/10.18632/aging.202151>
9. 2021) Real-world effectiveness of human papillomavirus vaccination against cervical cancer. J. Natl. Cancer Inst. 113, 1329-1335.
< , S. K., Dehlendorff, C., Belmonte, F. et al. (https://doi.org/10.1093/jnci/djab080>
10. 2022) Radiotherapy resistance: identifying universal biomarkers for various human cancers. J. Cancer Res. Clin. Oncol. 148, 1015-1031.
< , I., Rakina, M., Ivanyuk, E. et al. (https://doi.org/10.1007/s00432-022-03923-4>
11. 2014) starBase v2.0: decoding miRNA-ceRNA, miRNA-ncRNA and protein-RNA interaction networks from large-scale CLIP-Seq data. Nucleic Acids Res. 42(Database issue), D92-D97.
< , J. H., Liu, S., Zhou, H. et al. (https://doi.org/10.1093/nar/gkt1248>
12. 2021) EMX2OS plays a prognosis-associated enhancer RNA role in gastric cancer. Medicine (Baltimore) 100, e27535.
< , G. X., Tan, Y. Z., He, G. C. et al. (https://doi.org/10.1097/MD.0000000000027535>
13. 2016) Analyzing miRNA-lncRNA interactions. Methods Mol. Biol. 1402, 271-286.
< , M. D., Hatzigeorgiou, A. G. (https://doi.org/10.1007/978-1-4939-3378-5_21>
14. 2021) Adaptive radiotherapy in the management of cervical cancer: review of strategies and clinical implementation. Clin. Oncol. (R. Coll. Radiol.) 33, 579-590.
< , C. E., Barraclough, L. H., Nelder, C. L. et al. (https://doi.org/10.1016/j.clon.2021.06.007>
15. 2022) DAVID: a web server for functional enrichment analysis and functional annotation of gene lists (2021 update). Nucleic Acids Res. 50, W216-W221.
< , B. T., Hao, M., Qiu, J. et al. (https://doi.org/10.1093/nar/gkac194>
16. 2002) Cervical nodal metastases from occult primary: undifferentiated carcinoma versus squamous cell carcinoma. Head Neck 24, 361-369.
< , C. C., Luk, M. Y., Chow, S. M. et al. (https://doi.org/10.1002/hed.10054>
17. 2020a) Inhibition of miR-574-5p suppresses cell growth and metastasis and enhances chemosensitivity by targeting RNA binding protein QKI in cervical cancer cells. Naunyn Schmiedebergs Arch. Pharmacol. 393, 951-966.
< , R., Zhang, J., Wang, C. et al. (https://doi.org/10.1007/s00210-019-01772-6>
18. 2020b) LncRNA PTCSC3 inhibits the proliferation, invasion and migration of cervical cancer cells via sponging miR-574-5p. Clin. Exp. Pharmacol. Physiol. 47, 439-448.
< , R., Zhang, J., Wang, C. et al. (https://doi.org/10.1111/1440-1681.13186>
19. 2016) Cervical cancer: screening, diagnosis and staging. J. BUON 21, 320-325.
, P., Zervoudis, S., Manav, B. et al. (
20. 2021) Sample size re-estimation in clinical trials. Stat. Med. 40, 6133-6149.
< , P., Chow, S. C. (https://doi.org/10.1002/sim.9175>
21. 2020) LncRNA EMX2OS, regulated by TCF12, interacts with FUS to regulate the proliferation, migration and invasion of prostate cancer cells through the cGMP-PKG signaling pathway. Onco Targets Ther. 13, 7045-7056.
< , Z., Zhang, C., Chang, J. et al. (https://doi.org/10.2147/OTT.S243552>
22. 2021) Bioinformatics analysis of differentially expressed genes and pathways in the development of cervical cancer. BMC Cancer 21, 733.
< , B., Xi, S. (https://doi.org/10.1186/s12885-021-08412-4>
23. 2023) Identifying TME signatures for cervical cancer prognosis based on GEO and TCGA databases. Heliyon 9, e15096.
< , W. T., Qiu, W. R., Yu, W. K. et al. (https://doi.org/10.1016/j.heliyon.2023.e15096>
24. 2022) Exploration of the immune-related long noncoding RNA prognostic signature and inflammatory microenvironment for cervical cancer. Front. Pharmacol. 13, 870221.
< , H., Jiang, X., Fu, H. et al. (https://doi.org/10.3389/fphar.2022.870221>
25. 2021) The molecular feature of macrophages in tumour immune microenvironment of glioma patients. Comput. Struct. Biotechnol. J. 19, 4603-4618.
< , H., Luo, Y. B., Wu, W. et al. (https://doi.org/10.1016/j.csbj.2021.08.019>
26. 2023) EMX2OS targeting IGF2BP1 represses Wilms’ tumour stemness, epithelial-mesenchymal transition and metastasis. J. Genet. 102, 12.
< , H. M., Cui, M. Y., Chen, Z. H. (https://doi.org/10.1007/s12041-022-01411-9>
27. 2020) Role of non-coding RNAs and RNA modifiers in cancer therapy resistance. Mol. Cancer 19, 47.
< , X., Xie, K., Zhou, H. et al. (https://doi.org/10.1186/s12943-020-01171-z>
28. 2020) Immune-related four-lncRNA signature for patients with cervical cancer. Biomed Res. Int. 2020, 3641231.
< , J., Cao, B., Zhang, X. et al. (https://doi.org/10.1155/2020/3641231>